Welcome to our dedicated page for Graphite news (Ticker: GRPH), a resource for investors and traders seeking the latest updates and insights on Graphite stock.
Graphite Bio, Inc. (GRPH) is a clinical-stage biotechnology leader developing precision gene editing therapies for genetic disorders. This dedicated news hub provides investors and professionals with timely updates on scientific advancements, regulatory milestones, and strategic developments.
Access comprehensive coverage of GRPH's progress in next-generation genetic medicine, including clinical trial updates, research collaborations, and therapeutic pipeline advancements. Our curated collection focuses on the company's innovative use of homology directed repair (HDR) and targeted DNA integration technologies to address genetic diseases at their source.
Stay informed about critical announcements spanning peer-reviewed research publications, partnership agreements, and financial disclosures. All content is verified for accuracy and presented with clarity for both specialist and general audiences.
Bookmark this page for direct access to official GRPH updates and press releases. Visit regularly to track advancements in cutting-edge genetic medicines positioned to transform treatment paradigms for previously untreatable conditions.
Graphite Bio (NASDAQ: GRPH) announced that information regarding its Phase 1/2 CEDAR trial of GPH101 for sickle cell disease (SCD) will be presented at the 63rd American Society of Hematology Annual Meeting from December 11-14. GPH101 aims to correct the genetic mutation causing SCD, potentially curing the disease. The trial assesses safety, engraftment success, and gene correction rates. SCD affects around 100,000 people in the U.S., highlighting the urgent need for effective therapies.
Graphite Bio (NASDAQ: GRPH), a clinical-stage gene editing company, announced participation in a fireside chat at the Jefferies Gene Therapy/Editing Summit on October 28, 2021, at 4:30 p.m. ET. The chat will be webcast live on Graphite Bio's website, with an archived replay available for one month after the event. The company focuses on high-efficiency targeted gene integration to develop therapies aimed at curing serious diseases. Co-founded by experts in gene therapy, Graphite Bio aims to advance precision gene editing to correct mutations and replace disease-causing genes.
Graphite Bio announced promising preclinical data for its investigational therapy GPH101, aimed at curing sickle cell disease (SCD) through precise gene editing. The data, presented at the SCDAA National Convention, demonstrate the therapy's potential to correct the beta-globin mutation with minimal off-target effects, achieving over 60% gene correction rates in vitro. The company is on track to enroll its first patient in the Phase 1/2 CEDAR trial in the second half of 2021, signaling progress in addressing this serious condition affecting approximately 100,000 individuals in the U.S.
Graphite Bio (Nasdaq: GRPH) announced that their abstract on sickle cell disease (SCD) research has been accepted for a poster presentation at the 49th Annual Sickle Cell Disease Association of America National Convention, held virtually from October 12-16, 2021. The presentation will cover preclinical data supporting GPH101, a gene-edited therapy aimed at treating SCD by correcting the beta-globin gene mutation. SCD affects 100,000 people in the U.S., highlighting the need for effective therapies.
Graphite Bio, Inc. (NASDAQ: GRPH), a clinical-stage gene editing company, announced its participation in two upcoming virtual investor conferences. Management will engage in fireside chats at the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 2:45 p.m. ET, and at the Cantor Virtual Global Healthcare Conference on September 27, 2021, at 2:40 p.m. ET. The discussions will focus on their innovative gene editing technologies aimed at treating serious diseases.
Graphite Bio, Inc. (Nasdaq: GRPH) reported significant progress in its gene editing initiatives and second quarter 2021 financial results. The company completed an upsized IPO, raising $273.7 million. CEO Josh Lehrer highlighted the upcoming Phase 1/2 trial of GPH101 for sickle cell disease, with initial data expected by late 2022. As of June 30, 2021, cash reserves totaled $382.1 million. Research and development expenses for Q2 reached $12.7 million, contributing to a net loss of $17.5 million, or $3.45 per share.
Graphite Bio, Inc. (Nasdaq: GRPH) has successfully closed its initial public offering of 14 million shares at $17.00 each, totaling approximately $238 million. Additionally, underwriters exercised an option to purchase 2.1 million extra shares, bringing the total gross proceeds to $273.7 million. The offering, which closed on June 29, 2021, was managed by Morgan Stanley, BofA Securities, Cowen, and SVB Leerink. Graphite Bio specializes in gene editing therapies aimed at treating serious diseases through targeted gene integration.
Graphite Bio announced the pricing of its upsized initial public offering (IPO) of 14 million shares at $17.00 each, aiming for gross proceeds of approximately $238 million. The offering, with a 30-day option for underwriters to buy an additional 2.1 million shares, will commence trading on the Nasdaq under the ticker symbol “GRPH” on June 25, 2021, and is expected to close on June 29, 2021. Morgan Stanley, BofA Securities, Cowen, and SVB Leerink are the joint book-running managers for this offering.
